Full Press Release Details
Accessibility: Skip TopNav
Summit Corporation PLC : Exercise of Options
October 29, 2014 03:00 ET
Summit Therapeutics plc
Summit Therapeutics plc
Summit Corporation plc
('Summit' or 'the Company')
Oxford, UK, 29 October 2014 - Summit (AIM: SUMM) announces that on 28 October 2014 it received a notification of exercise in respect of options granted over 38,548 new ordinary shares in the Company at an exercise price of 60 pence per share and 17,737 new ordinary shares in the Company at an exercise price of 20 pence per share. Consequently the Company has issued and allotted 56,285 new ordinary shares in the Company. An application has been made for the 56,285 new ordinary shares to be admitted to AIM and admission is expected to occur on or around 3 November 2014.
Following this issue of equity the Company's issued share capital will comprise of 41,117,697 ordinary shares of 1 penny each.
For more information, please contact:
| Summit Glyn Edwards / Richard Pye (UK office) Erik Ostrowski (US office) | Tel: +44 (0)1235 443 951 +1 617 294 6607 |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7148 7900 |
| N+1 Singer (Broker) Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 |
| Peckwater PR (Financial public relations, UK) Tarquin Edwards | Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
| MacDougall Biomedical Communications (US media contact) Michelle Avery | Tel: +1 781 235 3060 mavery@macbiocom.com |